Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Association of age, race, and public health insurance with stage of cervical cancer at diagnosis in Brazil: Results of the EVITA cohort study (LACOG0215).

Sub-category:
Cervical Cancer

Category:
Gynecologic Cancer

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e17509

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e17509)

Author(s): Angelica Nogueira Rodrigues, Andreia Cristina de Melo, Aknar Calabrich, Eduardo Cronemberger, Kátia Luz Torres, Fernanda Damian, Rachel Jorge Dino Cossetti Leal, Carla Rameri Alexandre Silva De Azevedo, Allex Jardim da Fonseca, Yeni Verónica Neron, Joao Soares Nunes, André Lopes, Felipe Thome, Renato Leal, Giuliano Santos Borges, Paulo Ricardo Santos Nunes Filho, Facundo Zaffaroni, Gustavo Werutsky, Fernando C. Maluf; Brazilian Group of Gynecological Tumors - EVA, Porto Alegre, Brazil; Instituto Nacional do Câncer (INCA), Brazilian Group of Gynecological Oncology (EVA), Rio De Janeiro, Brazil; Clinica AMO, Brazilian Group of Gynecological Oncology (EVA), Salvador, Brazil; Centro Regional Integrado de Oncologia, Brazilian Group of Gynecological Oncology (EVA), Fortaleza, Brazil; FCECON - Amazonas, Brazilian Group of Gynecological Oncology (EVA), Manaus, Brazil; Centro de Pesquisa em Oncologia, Brazilian Group of Gynecological Oncology (EVA), Porto Alegre, Brazil; Hospital Aldenora Bello, Brazilian Group of Gynecological Oncology (EVA), São Luís, Brazil; Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Brazilian Group of Gynecological Oncology (EVA), Recife, Brazil; Hospital Geral de Roraima, Brazilian Group of Gynecological Oncology (EVA), Boa Vista, Brazil; Centro de Pesquisas Oncológicas-CEPON, Brazilian Group of Gynecological Oncology (EVA), Florianopolis-SC, Brazil; Hospital Erasto Gaertner, Brazilian Group of Gynecological Oncology (EVA), Curitiba, Brazil; Instituto Brasileiro de Controle do Câncer, Brazilian Group of Gynecological Oncology (EVA), São Paulo, Brazil; Hospital Sao Vicente de Paulo, Brazilian Group of Gynecological Oncology (EVA), Passo Fundo, Brazil; Hospital Universitário Walter Cantídio, Brazilian Group of Gynecological Oncology (EVA), Fortaleza, Brazil; Centro de Novos Tratamentos Itajai/Hospital Santo Antonio, Brazilian Group of Gynecological Oncology (EVA), Itajai, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Hospital Beneficência Portuguesa de São Paulo e Hospital Israelita Albert Einstein, Brazilian Group of Gynecological Oncology (EVA), São Paulo, Brazil

Abstract Disclosures

Abstract:

Background: Cervical cancer (CC) is the fourth most common malignancy in women worldwide and third in Brazil. It is a health problem in in low and middle-income countries (LMIC), where most screening programs have failed to achieve its potential and 85% of the global disease burden is. Therefore, studies aiming to describe the population of patients in those countries are of uttermost importance for planning public health policies. EVITA is the major prospective CC cohort study performed in Brazil. Here we present patients’ baseline characteristics and diagnostics features. Methods: Prospective, observational study, within 16 sites in Brazil. Main eligibility criteria were 18 years-old, newly diagnosed stage I to IV invasive CC and signed informed consent. Data was collected during medical visits and from medical charts. Results are expressed as mean (± SD) and relative frequencies. Chi-square and t tests were used for comparisons. Results: A total of 631 patients were included from January 2016 to November 2017. Mean age at diagnosis was 49.3y (±13.9). Most patients had £ 8 years of formal education (49.8%), personal income £ one minimum wage (88.7%) and were treated in public health system (95.2%). 52% were smokers, 59% were had used oral contraceptives and 2% were HIV+. Of note, 87% patients reported at least one previous pap test. Squamous cell carcinoma was the most frequent histology (73.9%). Regarding stage, 12.8% of the patients were stage I, 35.2% stage II, 37.9% stage III and 10.1% stage IV at diagnosis. Factors associated with advanced stage (II-IV) at diagnosis were: older age (50.0y vs 44.6y; P .001), non-white race (89.5% vs 81.7%; P .008) and public health insurance (87.2% vs 73.1%; P .038). Conclusions: Our study shows that 82% of CC patients are stage II or more at diagnosis In Brazil and that advanced stage at diagnosis is associated with sociodemographic characteristics. It is a disease with poor prognosis, high health costs and significant social impact. Awareness campaigns towards prevention and early detection focusing on this high risk population are key for CC control in LMICs.

 
Other Abstracts in this Sub-Category:

 

1. Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5502 First Author: Daniel Jacob Margul
Category: Gynecologic Cancer - Cervical Cancer

 

2. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5511 First Author: Ursula A. Matulonis
Category: Gynecologic Cancer - Cervical Cancer

 

3. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5522 First Author: Hyun Cheol Chung
Category: Gynecologic Cancer - Cervical Cancer

 

More...